EVOKE PHARMA INC's ticker is EVOK and the CUSIP is 30049G104. A total of 14 filers reported holding EVOKE PHARMA INC in Q2 2016. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $682,000 | -17.3% | 275,000 | 0.0% | 0.78% | +11.3% |
| Q3 2018 | $825,000 | +19.9% | 275,000 | 0.0% | 0.70% | +19.1% |
| Q2 2018 | $688,000 | +20.3% | 275,000 | 0.0% | 0.58% | -0.3% |
| Q1 2018 | $572,000 | -8.0% | 275,000 | 0.0% | 0.59% | +7.1% |
| Q4 2017 | $622,000 | -17.3% | 275,000 | +22.2% | 0.55% | -14.8% |
| Q3 2017 | $752,000 | +67.9% | 225,000 | +28.6% | 0.64% | +8.2% |
| Q2 2017 | $448,000 | -17.5% | 175,000 | 0.0% | 0.59% | -27.5% |
| Q1 2017 | $543,000 | +42.5% | 175,000 | +214.4% | 0.82% | +565.9% |
| Q2 2016 | $381,000 | +34.6% | 55,660 | 0.0% | 0.12% | +7.0% |
| Q1 2016 | $283,000 | +53.8% | 55,660 | 0.0% | 0.12% | +69.1% |
| Q4 2015 | $184,000 | +13.6% | 55,660 | 0.0% | 0.07% | -1.4% |
| Q3 2015 | $162,000 | -44.3% | 55,660 | 0.0% | 0.07% | -26.6% |
| Q2 2015 | $291,000 | -23.4% | 55,660 | +3.4% | 0.09% | -15.3% |
| Q1 2015 | $380,000 | – | 53,839 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 242,500 | $1,962,000 | 1.69% |
| SOPHROSYNE CAPITAL LLC | 49,000 | $397,000 | 0.40% |
| LMR Partners LLP | 23,882 | $187,000 | 0.02% |
| GEODE CAPITAL MANAGEMENT, LLC | 10,276 | $80,000 | 0.00% |
| BlackRock Investment Management, LLC | 489 | $4,000 | 0.00% |
| MORGAN STANLEY | 500 | $4,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 84 | $1,000 | 0.00% |
| VANGUARD GROUP INC | 48,394 | $378,000 | 0.00% |
| UBS AG | 727 | $6,000 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 33,500 | $271,000 | 0.00% |